Amendments to the Claims:

Claims 1-12 (Cancelled).

13. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated Varicella Zoster Virus IE63 protein and a pharmaceutically acceptable excipient, wherein the composition induces a humoral or cellular immune response without significant, adverse side effects.

14. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated nucleic acid encoding IE63, wherein the composition induces a humoral or cellular immune response without significant, adverse side effects.

15. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising other VZV antigens.

16. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 15, wherein the other VZV antigens are selected from the group, gpI, gpII, gpIII, gpIV, gpV or IE62 or anchorless derivatives thereof.

17. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising an adjuvant.

18. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 17, wherein the adjuvant preferentially induces a TH1 response.

19. (Previously presented): A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 18, wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

20. (Currently amended). A method of producing a safe and effective immunogenic pharmaceutical composition comprising an isolated Varicella Zoster virus IE63 protein, or an isolated nucleic acid encoding a Varicella Zoster virus IE63 protein, comprising mixing said protein or said nucleic acid with a human pharmaceutically acceptable excipient.

21. (Previously presented): A method as claimed in claim 20, wherein the excipient comprises an adjuvant.